Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Invivyd Inc (IVVD)

Invivyd Inc (IVVD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 519,864
  • Shares Outstanding, K 233,123
  • Annual Sales, $ 25,380 K
  • Annual Income, $ -169,930 K
  • EBIT $ -62 M
  • EBITDA $ -59 M
  • 60-Month Beta 0.61
  • Price/Sales 20.39
  • Price/Cash Flow N/A
  • Price/Book 5.56

Options Overview Details

View History
  • Implied Volatility 189.66% (+2.58%)
  • Historical Volatility 141.67%
  • IV Percentile 23%
  • IV Rank 7.33%
  • IV High 1,010.24% on 06/27/25
  • IV Low 124.72% on 03/18/25
  • Expected Move (DTE 12) 0.70 (31.26%)
  • Put/Call Vol Ratio 8.82
  • Today's Volume 491
  • Volume Avg (30-Day) 1,531
  • Put/Call OI Ratio 0.79
  • Today's Open Interest 20,212
  • Open Int (30-Day) 19,246
  • Expected Range 1.53 to 2.93

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.06
  • Number of Estimates 1
  • High Estimate -0.06
  • Low Estimate -0.06
  • Prior Year -0.15
  • Growth Rate Est. (year over year) +60.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.38 +61.01%
on 11/07/25
3.07 -27.36%
on 11/17/25
+0.71 (+46.71%)
since 11/05/25
3-Month
1.05 +112.38%
on 09/29/25
3.07 -27.36%
on 11/17/25
+1.09 (+95.61%)
since 09/05/25
52-Week
0.35 +528.88%
on 01/30/25
3.07 -27.36%
on 11/17/25
+1.66 (+290.68%)
since 12/05/24

Most Recent Stories

More News
Invivyd to Participate at the 8th Annual Evercore Healthcare Conference

NEW HAVEN, Conn., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that management will participate in a fireside chat at the 8 th Annual Evercore Healthcare Conference...

IVVD : 2.23 (+0.45%)
Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness

VBY329 is designed for the prevention of Respiratory Syncytial Virus (RSV) infections in newborns, infants, and children, and results from Invivyd’s proprietary antibody discovery technology platform...

IVVD : 2.23 (+0.45%)
Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants

NEW HAVEN, Conn., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced the pricing of an underwritten public offering of 44,000,000 shares of its common stock at an...

IVVD : 2.23 (+0.45%)
Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights

PEMGARDA® (pemivibart) net product revenue of $13.1 million reported for Q3 2025, representing 41% growth year-over-year and 11% growth quarter-over-quarter October 2025 ending cash and cash equivalents...

IVVD : 2.23 (+0.45%)
Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025

NEW HAVEN, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced...

IVVD : 2.23 (+0.45%)
Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

NEW HAVEN, Conn., Oct. 28, 2025 (GLOBE NEWSWIRE) -- WHAT: Invivyd, Inc. (Nasdaq: IVVD) is hosting the previously announced live webcast to present an overview of the company’s REVOLUTION clinical...

IVVD : 2.23 (+0.45%)
Invivyd’s VYD2311 Receives FDA Clearance for Trials

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Invivyd (...

IVVD : 2.23 (+0.45%)
Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

The DECLARATION (safety and efficacy vs. placebo) and LIBERTY (exploratory safety head-to-head and combination with mRNA-based COVID vaccination) clinical trials are expected to begin around year-end 2025;...

IVVD : 2.23 (+0.45%)
Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors

NEW HAVEN, Conn., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ: IVVD) today announced the appointment of Paul B. Bolno, M.D., to its Board of Directors and as a member of the Compensation...

IVVD : 2.23 (+0.45%)
Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer

NEW HAVEN, Conn., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced the appointment of Kristie Kuhl as Chief Communications Officer. Ms. Kuhl will lead the Company’s communications...

IVVD : 2.23 (+0.45%)

Business Summary

INVIVYD INC. is a biopharmaceutical company. It involved in developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. INVIVYD INC., formerly known as Adagio Therapeutics, is based in WALTHAM, Mass.

See More

Key Turning Points

3rd Resistance Point 2.44
2nd Resistance Point 2.36
1st Resistance Point 2.30
Last Price 2.23
1st Support Level 2.16
2nd Support Level 2.08
3rd Support Level 2.02

See More

52-Week High 3.07
Last Price 2.23
Fibonacci 61.8% 2.03
Fibonacci 50% 1.71
Fibonacci 38.2% 1.39
52-Week Low 0.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar